Monitor for the specific offering size in the 8-K or press release. The dilutive PIPE signals ongoing financial distress and increases delisting risk. Traders should expect further downside pressure on the stock.
Price Chart
Executive Summary
Scinai Immunotherapeutics is raising capital through a PIPE offering of ADSs at $0.48 per share with Series A and B warrants attached, alongside a registration rights agreement. The exact offering size is undisclosed but given the company's $3M market cap and prior going concern warning, this is a highly dilutive emergency financing.
Key Facts
- ADSs sold at $0.48 per ADS with Series A warrants ($0.55 exercise, 5-year) and Series B warrants ($0.48 exercise, 2-year) covering 100% of ADSs
- Registration rights agreement filed to register resale of the securities
- Company has prior going concern warning and delisting risk from 20-F filed 26 days ago
- Lock-up agreements with directors and officers
- Use of proceeds for working capital and general corporate purposes, including up to EUR 250,000 to European Investment Bank
Financial Impact
Highly dilutive relative to $3M market cap; offering size not disclosed but material given 20-F indicates only $1.6M cash and $8.3M net loss
Risk Factors
- Massive shareholder dilution from the offering and warrant exercises
- Nasdaq delisting risk remains high given sub-$1 bid price and weak fundamentals
- Going concern uncertainty persists despite capital raise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-048002 |
| Document: ea028778301ex10-2.htm | 0001213900-26-048002 |
| Document: ea028778301ex4-3.htm | 0001213900-26-048002 |
| Document: ea028778301ex4-2.htm | 0001213900-26-048002 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5310 (−22.06%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5310 (+29.39%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5310 (+29.43%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5310 (+41.10%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5310 (−56.83%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5310 (+56.48%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5310 (−68.58%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5310 (+81.50%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5310 (−93.80%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5310 (+57.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers